Ans Biotech company information, Employees & Contact Information

AbbVie, Regeneron and Sanofi help fund $80M series A round for Tregs specialist Zag Bio Fierce Biotech

Lilly buys cash-strapped Adverum for eye disease gene therapy Fierce Biotech

Amid the dip, biotech execs share silver linings in a tumultuous environment Fierce Biotech

GLD flexes muscle-wasting ambitions, launching Altagenics with an assist from Heligenics Fierce Biotech

British biotech emerges with $70M series A and midstage arthritis asset Fierce Biotech

Novo vs. KBP: How a $1.3B deal turned into a fraud accusation and an international legal fight Fierce Biotech

Lilly opens Gate to new small-molecule drug class with $856M biobucks deal Fierce Biotech

53 biotech leaders urge FDA not to restrict mifepristone access over 'fatally flawed' report Fierce Biotech

Adaptimmune sells 4 cell therapies to pharma for $55M, plans layoffs Fierce Biotech

Pfizer expands AI-powered small-molecule discovery collab with XtalPi Fierce Biotech

Unity disbands workforce as it searches for strategic path forward, while Mammoth cuts 24 roles Fierce Biotech

Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers Fierce Biotech

NIH chief calls for immediate research review, dangling threat of project termination Fierce Biotech

As BioMarin searches for 'clever science,' its R&D chief warns innovation could be hit by NIH fund drought Fierce Biotech

Incyte pens $885M biobucks AI pact to use Genesis' GEMS to develop new drugs Fierce Biotech

AbbVie takes Genmab to court, accusing partner of being 'willfully blind' to ADC trade secret theft Fierce Biotech

Sticky, sticky, sticky: Neomorph tacks on another Big Pharma glue degrader deal with $1.6B AbbVie pact Fierce Biotech

NIH grants powered $94B in economic activity in 2024 and supported more than 400K jobs: report Fierce Biotech

ASH: New Gilead-Arcellx data build CAR-T's case against Carvykti in advanced multiple myeloma Fierce Biotech

Aldeyra shuffles RASP pack, dropping and swapping assets in response to data Fierce Biotech

Eli Lilly and Nvidia team up to build 'most powerful' supercomputer in pharma Fierce Biotech

De-Risking Clinical Development: Strategic Multipliers in Global Trials Fierce Biotech

Boehringer Ingelheim digs in on ADCs, offering up to $991M to license cancer prospect from Korea's AimedBio Fierce Biotech

2025 M&A up in value and deal count after year of 'conservatism and recovery': Leerink Partners Fierce Biotech

10 ways COVID-19 rocked biotech—plus an honorable mention for omicron Fierce Biotech

An innovation supply chain: Pfizer taps Flagship for 10-program pipeline pact worth $7B in biobucks Fierce Biotech

Ipsen hands back Sutro's ROR1 ADC at center of $875M deal Fierce Biotech

BridgeBio aces phase 3 rare disease test, clearing path to FDA Fierce Biotech

Scorpion spinout raises $177M to advance preclinical assets after 2 clinical programs sold to Pierre Fabre Fierce Biotech

Incyte scraps BET inhibitor against backdrop of safety concerns for the drug class Fierce Biotech

Phase 2 data will drive biopharma VC investments next year: PitchBook Fierce Biotech

AI and Machine Learning Fierce Biotech

ARPA-H is 'open for business' to provide lifeline for a struggling biotech industry Fierce Biotech

I-Mab buys Bridge Health for $3M-plus to strengthen pivot to CLDN18.2 bispecific Fierce Biotech

New AI drug discovery powerhouse Xaira rises with $1B in funding Fierce Biotech

Frontier Medicines launches with $67M and biotech veteran Varma as CEO Fierce Biotech

Novartis goes big for neuroscience with $12B deal for late-stage dystrophy biotech Avidity Fierce Biotech

AI drug hunter Exscientia chops down 'rapidly emerging pipeline' to focus on 2 main oncology programs Fierce Biotech

IO lays off 50% of employees after FDA derails cancer vaccine approval plan Fierce Biotech

Puerto Rico on Gene & Cell Therapy: An Unparalleled Proposal for Non-Dilutive Funding Fierce Biotech

iTeos, reeling from TIGIT fail, becomes latest prize for deal-hungry Concentra Fierce Biotech

With $370M debut, Candid Therapeutics is upfront about goal to lead a coming T-cell engager wave Fierce Biotech

BIO CEO Michelle McMurry-Heath steps down days after media attention on internal clashes Fierce Biotech

Vivocore combines InterVivo, Transpharmation to form neuroscience CRO with an interest in psilocybin Fierce Biotech

Chutes & Ladders—Moderna elevates manufacturing lead Andres to new executive strategy role Fierce Biotech

Hungry for more, Lilly tops off weight loss pipeline with $1.9B deal to acquire Versanis Fierce Biotech

Tempest lays off 80% of workforce to ride out cash crunch Fierce Biotech

Chutes & Ladders—Pfizer's Mikael Dolsten steps down as AbbVie's R&D org switches leaders Fierce Biotech

Intellia pauses phase 3 CRISPR trials after patient is hospitalized Fierce Biotech

Pheon nabs $68M to ready clinical launch based on ADC-featured pipeline Fierce Biotech

UniQure, Arbutus and HilleVax all lay off staff as biotechs streamline operations and cut costs Fierce Biotech

Pfizer-backed CellCentric secures $120M for further myeloma trials Fierce Biotech

Amgen's monthly obesity drug matches competition in phase 2, but investors are unimpressed Fierce Biotech

Sanofi cuts staff in Belgium as early-stage research dwindles Fierce Biotech

GSK heads back to Hansoh, paying $185M upfront for another ADC Fierce Biotech

Kymera Therapeutics, fresh off a $2B Sanofi biobucks pact, guns for an IPO Fierce Biotech

Roivant, in an unexSPACted twist, wants to bring Immunovant back into the fold Fierce Biotech

Navigating the complexities of oncology clinical trials in an increasingly competitive landscape Fierce Biotech

Sanofi drops RSV vaccine for toddlers after phase 3 trial heads for failure Fierce Biotech

Novo Nordisk R&D spend jumps 35% thanks to soaring sales as oral obesity plans advance Fierce Biotech

Months after an executive exodus, Exicure tells 66% of remaining staff to exit as it suspends all R&D work Fierce Biotech

BioVie blames protocol errors at trial sites for phase 3 Alzheimer’s drug fail as stock craters Fierce Biotech

Report: Every dollar of NIH research funding doubles in economic returns Fierce Biotech

Ipsen gets hot on cold tumors, inking $1.2B biobucks deal for Marengo's T-cell engagers Fierce Biotech

Trump HHS reevaluating Biden administration's $590M bird flu vaccine contract with Moderna: Bloomberg Fierce Biotech

Immunovant's plan to restart IMVT-1401 development falls flat as CMO makes an exit Fierce Biotech

Kyverna's CAR-T relapse in lupus dents autoimmune hopes amid biotech gold rush Fierce Biotech

Senate committee opposes Trump’s NIH cuts, proposes $400M budget increase Fierce Biotech

Health Logic Interactive is developing an Innovative POC Digital Device for CKD Fierce Biotech

Viela Bio, China's Hansoh pen development pact potentially worth $220M-plus Fierce Biotech

Using an old Merck drug, Menlo hopes to scratch an itch with $98M IPO Fierce Biotech

Concentra finds latest acquisition attempt harder to swallow as Atea rejects 'undervalued' offer Fierce Biotech

Patient Centricity and the Role of the CRO Fierce Biotech

Amgen Joins With LabCentral To Support Life-Sciences And Biotech Startups In Cambridge, Massachusetts Fierce Biotech

China’s KBP gains GlaxoSmithKline executive as chief, an American headquarters and a cash boost Fierce Biotech

Seeking an edge in a fiercely fought field, Bristol-Myers pays Halozyme $105M to access I-O delivery tech Fierce Biotech

Stryker strikes again, acquiring brain surgery devicemaker Nico Fierce Biotech

20 Big Pharma and biotech mobile apps - 2013 Fierce Biotech